SHTG Daily Digest — Weiss Lab
A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.
17 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity SHTG Daily Digest — Weiss Lab-yhteisöön!